In my professional employment I am responsible for supporting internal clinical development teams, establishing and maintaining external partnerships in academia and the pharmaceutical industry, delivering the quantitative analysis of medical imaging and neurophysiological studies, and the application of imaging biomarkers to early-phase drug development.
I am particularly interested in the interface between data acquisition, image processing, mathematical modeling and statistical inference. I have experience with a wide range of therapeutic areas in the pharmaceutical industry including neurology, psychiatry, musculoskeletal, metabolic and oncology.
et al., 2017, MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial., Eur Radiol
et al., 2017, The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial, Journal of Urology, Vol:197, ISSN:0022-5347, Pages:1006-1013
et al., 2014, Automated Identification of Brain New Lesions in Multiple Sclerosis Using Subtraction Images, Journal of Magnetic Resonance Imaging, Vol:39, ISSN:1053-1807, Pages:1543-1549
et al., 2013, Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease, Journal of Neuroscience, Vol:33, ISSN:0270-6474, Pages:2147-2155
et al., 2013, Dynamic contrast-enhanced magnetic resonance imaging for characterising nasopharyngeal carcinoma: comparison of semiquantitative and quantitative parameters and correlation with tumour stage., Eur Radiol, Vol:23, Pages:1495-1502